Efficacy of Natalizumab extended dosing in multiple sclerosis: a retrospective multicenter analysis

被引：0

作者：

Ryerson, L. Zhovtis ^{[1
]}

Herbert, J. ^{[1
]}

Tornatore, C. ^{[2
]}

Foley, J. ^{[3
]}

Weinstock-Guttman, B. ^{[4
]}

Kister, I. ^{[1
]}

Pandey, K. ^{[5
]}

Hojnacki, D. ^{[4
]}

Remington, G. ^{[6
]}

Frohman, T. ^{[6
]}

Major, E. ^{[7
]}

Douek, D. ^{[8
]}

Qureshi, S. ^{[6
]}

Beh, J. ^{[6
]}

Okuda, D. ^{[6
]}

Utomo, P. ^{[1
]}

Hoyt, T. ^{[3
]}

Chamot, E. ^{[9
]}

Bucello, M. ^{[4
]}

Ahsan, I. ^{[4
]}

Kolb, C. ^{[4
]}

Frohman, E. ^{[6
]}

机构：

[1] NYU, Langone Med Ctr, New York, NY USA

[2] Georgetown Univ Hosp, Neurol, Washington, DC 20007 USA

[3] Rocky Mt MS Clin, Salt Lake City, UT USA

[4] SUNY Buffalo, Neurol, Buffalo, NY 14260 USA

[5] Barnabas Hlth MS Ctr, Neurol, Livingston, NJ USA

[6] Univ Texas SW Med Ctr Dallas, Neurol, Dallas, TX 75390 USA

[7] NINDS, Bethesda, MD 20892 USA

[8] Natl Inst Allergy & Immunol, Bethesda, MD USA

[9] Univ Alabama Birmingham, Birmingham, AL USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P287

引用

页码：194 / 195

页数：2

共 50 条

[1] Personalized extended interval dosing of natalizumab in multiple sclerosis: a prospective multicenter trial
van Kempen, Z.
Hoogervorst, E.
Kalkers, N.
Mostert, J.
Lissenberg-Witte, B.
de Vries, A.
ten Brinke, A.
van Oosten, B.
Barkhof, F.
Wattjes, M.
Teunissen, C.
Uitdehaag, B.
Rispens, T.
Killestein, J.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 735 - 736
[2] Extended interval dosing of natalizumab in multiple sclerosis
Ryerson, L. Zhovtis
Frohman, T. C.
Foley, J.
Kister, I.
Weinstock-Guttman, B.
Tornatore, C.
Pandey, K.
Donnelly, S.
Pawate, S.
Bomprezzi, R.
Smith, D.
Kolb, C.
Qureshi, S.
Okuda, D.
Kalina, J.
Rimler, Z.
Green, R.
Monson, N.
Hoyt, T.
Bradshaw, M.
Fallon, J.
Chamot, E.
Bucello, M.
Beh, S.
Cutter, G.
Major, E.
Herbert, J.
Frohman, E. M.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (08): : 885 - 889
[3] Natalizumab extended interval dosing: efficacy and safety profile analysis from a Portuguese Multiple Sclerosis Center
Ferreira, P.
Oliveira, D.
Boleixa, D.
Ferreira, I.
da Silva, A. Martins
Samoes, R.
Santos, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 526 - 526
[4] Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients
Petrzalka, M.
Meluzinova, E.
Mojzisova, H.
Libertinova, J.
Rockova, P.
Nema, E.
Elisak, M.
Marusic, P.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (01) : 79 - 83
[5] Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis: a prospective multicenter trial in The Netherlands
Toorop, A.
Rispens, T.
Uitdehaag, B.
Killestein, J.
van Kempen, Z.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 569 - 569
[6] Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis - a prospective multicenter trial in the netherlands
Toorop, A.
Rispens, T.
Uitdehaag, B.
Killestein, J.
Van Kempen, Z.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 226 - 227
[7] Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
Rabea, Eslam Mohammed
Belal, Mohamed Mohamed
Hafez, Abdelrahman H.
Elbanna, Ashraf Hassan
Khalifa, Mahmoud Ahmed
Nourelden, Anas Zakarya
Mahmoud, Nada H.
Zaazouee, Mohamed Sayed
ACTA NEUROLOGICA BELGICA, 2024, 124 (02) : 407 - 417
[8] Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
Eslam Mohammed Rabea
Mohamed Mohamed Belal
Abdelrahman H. Hafez
Ashraf Hassan Elbanna
Mahmoud Ahmed Khalifa
Anas Zakarya Nourelden
Nada H. Mahmoud
Mohamed Sayed Zaazouee
Acta Neurologica Belgica, 2024, 124 : 407 - 417
[9] Extended interval dosing natalizumab and cognitive function in relapsing-remitting multiple sclerosis patients: a retrospective audit
Mc Manus, E.
Clark, K.
Macniven, J.
Schepel, J.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 503 - 504
[10] Long-term effectiveness of extended interval dosing of natalizumab in multiple sclerosis
Ryerson, L. Zhovtis
Lee, S.
Bacon, T.
Toth, E.
Chinea, R.
Gragui, D.
Kister, I.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 358 - 359

← 1 2 3 4 5 →